BMA BIOMEDICALS

Biotinylated Monoclonal Antibody to Human (Rat) EMAP II

Endothelial-Monocyte-Activating Polypeptide II

EMAP II is a proinflammatory cytokine and chemoattractant for macrophages. The 20kDa mature peptide binds to endothelial cells and leukocytes like macrophages. EMAP II activates endothelial cells, by elevation of cytosolic free calcium concentration, release of von Willebrand factor, induction of tissue factor, and expression of adhesion molecules E-selectin and P-selectin. It further activates resting monocytes by elevating cytosolic free Ca^{2+}, inducing TNFα and tissue factor, and stimulating chemotaxis. EMAP II has been shown in a tumour model to sensitize the local tumour vasculature to the action of TNFα, rendering resistant tumours sensitive to immunotherapy by TNFα. This monoclonal antibody was obtained by immunisation with human EMAP II and reacts with rat tissues as well.

TECHNICAL AND ANALYTICAL CHARACTERISTICS

Product Number:	T-1131 (Lot 01PB1705)
Clone:	546-2
Host species, isotype:	Mouse IgG1
Quantity:	100µg
Format:	Affinity purified, biotinylated, lyophilized
	Reconstitute by adding 0.5ml distilled water. This stock solution contains 0.2mg/ml IgG, phosphate buffered saline pH 7.2 (PBS), 5mg/ml bovine serum albumin (BSA) as a stabilizer and 0.05% (v/v) Kathon™ CG as a preservative.
Stability:	Original vial: 1 year at 4° - 8°C from date of purchase. Stock solution and aliquots thereof: 1 year at -20°C. Avoid freeze-thaw cycles.
Applications:	Tested for immunohistochemistry (IHC); has been described to work in ELISA and Western Blot.
	Approximate working dilution for IHC: Frozen sections: 5µg/ml (1:40) Paraffin sections: 5-10µg/ml (1:20-1:40), pretreatment in microwave with citrate buffer for antigen retrieval is recommended
	Optimal dilutions should be determined by the end user
	Suggested positive control: rat spleen
	Please see **www.bma.ch** for protocols and general information

©2024 BMA BIOMEDICALS, Rheinstrasse 28-32, CH-4302 Augst (Switzerland)
Phone: +41 61 811 6222, Email: info@bma.ch, www.bma.ch

Immunogen:	Recombinant human EMAP II
Protein database:	human-Q12904, rat-Q9EPV3
Antigen, epitope:	The antigen is EMAP II, the epitope has not been further characterized.
Specificity:	**Human:** EMAP II
	Other species: rat

Selected references

Schluesener, H.J. et al.: Localization of Endothelial-Monocyte-Activating Polypeptide II (EMAP II), a Novel proinflammatory cytokine, to lesions of experimental autoimmune encephalomyelitis, neuritis and uveitis: expression by monocytes and activated microglial cells. Glia **20,** 365-372 (1997)

Schluesener, H.J. et al.: Effects of autoantigen and dexamethasone treatment on expression of endothelial-monocyte activating polypeptide II and allograft-inflammatory factor-1 by activated macrophages and microglial cells in lesions of experimental autoimmune encephalomyelitis, neuritis and uveitis. Acta Neuropathol. **97,** 119-126 (1999).

©2024 BMA BIOMEDICALS, Rheinstrasse 28-32, CH-4302 Augst (Switzerland)
Phone: +41 61 811 6222, Email: info@bma.ch, www.bma.ch

For in vitro research only. This product contains Kathon™ CG as a preservative.

©2024 BMA BIOMEDICALS, Rheinstrasse 28-32, CH-4302 Augst (Switzerland)
Phone: +41 61 811 6222, Email: info@bma.ch, www.bma.ch